Back to Search
Start Over
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
- Source :
- NPJ Precision Oncology, npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
- Publication Year :
- 2021
- Publisher :
- Nature Publishing Group UK, 2021.
-
Abstract
- The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition.
- Subjects :
- 0301 basic medicine
Cancer Research
medicine.medical_treatment
Antigen presentation
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cancer
Cancer immunotherapy
Immunotherapy
Biology
medicine.disease
Article
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Immune system
Oncology
Immunoediting
030220 oncology & carcinogenesis
medicine
Cancer research
Lung cancer
Ovarian cancer
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 2397768X
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- NPJ Precision Oncology
- Accession number :
- edsair.doi.dedup.....3892e0783bc95867ab723a0eed7ebb1e